TY - JOUR
T1 - Collateral Circulation in Thrombectomy for Stroke after 6 to 24 Hours in the DAWN Trial
AU - Liebeskind, David S.
AU - Saber, Hamidreza
AU - Xiang, Bin
AU - Jadhav, Ashutosh P.
AU - Jovin, Tudor G.
AU - Haussen, Diogo C.
AU - Budzik, Ronald F.
AU - Bonafe, Alain
AU - Bhuva, Parita
AU - Yavagal, Dileep R.
AU - Hanel, Ricardo A.
AU - Ribo, Marc
AU - Cognard, Christophe
AU - Sila, Cathy
AU - Hassan, Ameer E.
AU - Smith, Wade S.
AU - Saver, Jeffrey L.
AU - Nogueira, Raul G.
N1 - Funding Information:
Dr Liebeskind reports the following: Consultant as imaging core lab for Cerenovus, Genentech, Medtronic, Rapid Medical, Stryker, Vesalio. Dr Jovin reports the following: Consultant at Cerenovus (steering committee/Data and Safety Monitoring Board–modest), Stryker Neurovascular (principal investigator DAWN [Diffusion-Weighted Imaging or Computed Tomography Perfusion Assessment With Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention With Trevo]-unpaid), holds Stock at Anaconda, Blockade Medical, Route 92, Corindus, FreeOx Biotech, Viz.ai, Silk Road. He reports other from Methinks, personal fees from Contego Medical, grants from Medtronic. Dr Haussen reports the following: Consultant for Stryker, Vesalio and Cerenovus; stock options from Viz.ai. Dr Bonafe reports the following: Consultant for Stryker, Microvention, Balt, and Phenox. Dr Yavagal reports the following: Consultant for Medtronic, Neural Analytics, Cerenovus, Rapid Medical (Steering Committee Member of TIGER [Treatment With Intent to Generate Endovascular Reperfusion] Clinical Trial & Consultant); Stryker (funding for patient enrollment in DAWN trial as sponsor of the trial). He reports other from Poseydon, personal fees from Vascular Dynamics, and other from NeuroSave outside the submitted work. Dr Hanel reports the following: Research Grant from Medtronic, Stryker, Microvention, Cerenovus Consultant: Stryker, Medtronic, Cerenovus, Microvention; Stockholder in Neurvana, Elum, EndoStream, Three Rivers Medical, Inc, Rist, Cerebrotech, InNeuroCo; Scientific Advisor for MIVI Neuroscience, Inc, Elum, Three Rivers Medical, Inc, Shape Medical. He reports personal fees from Balt, personal fees from Phenox. Dr Ribo reports the following: Consultant for Cerenovus, Medtronic, Stryker, Apta Targets, Anaconda Biomed and has equity ownership interest in Anaconda Biomed. He reports other from Methinks. Dr Cognard reports the following: Consultant for Stryker, Microvention, Medtronic, and Cerenovus. He reports personal fees from MIVI. Dr Sila reports the following: Honoraria and administrative analysis from Medtronic; Grants from Stryker. She reports other from University Hospitals Cleveland Medical Center during the conduct of the study. Dr Hassan reports the following: Consultant, speaker, and proctor for Medtronic, Stryker, and Microvention and a consultant/speaker for Penumbra, BALT, GE Heathcare, Viz.ai. He reports personal fees from SCIENTIA, IMPERATIVE CARE, Q’APEL, GENENTECH, PROXIMIE, NOVASIGNAL AND VESALIO during the conduct of the study. Dr Smith reports the following: Compensation from Stryker, Inc, as Data and Safety Monitoring Board chair for the study; ownership interest in MindRhythm and inventor on a University of California patent. Dr Saver reports the following: Employee of the University of California; The University of California has patent rights in retrieval devices for stroke; served as an unpaid site investigator in multicenter trials sponsored by Medtronic, Stryker, and Neuravi/Cerenovus for which the University of California Regents received payments on the basis of clinical trial contracts for the number of subjects enrolled; received contracted hourly payments from Medtronic, Stryker, and Neuravia/Cerenovus and contracted stock options from Rapid Medical for services as a scientific consultant advising on rigorous trial design and conduct. Dr Nogueira reports consulting fees for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Hybernia, Imperative Care, Medtronic, Phenox, Prolong Pharmaceuticals, Stryker Neurovascular, Synchron, and stock options for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, and Perfuze. The other authors report no conflicts.
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Background and Purpose: Collaterals govern the pace and severity of cerebral ischemia, distinguishing fast or slow progressors and corresponding therapeutic opportunities. The fate of sustained collateral perfusion or collateral failure is poorly characterized. We evaluated the nature and impact of collaterals on outcomes in the late time window DAWN trial (Diffusion-Weighted Imaging or Computed Tomography Perfusion Assessment With Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention With Trevo). Methods: The DAWN Imaging Core Lab prospectively scored collateral grade on baseline computed tomography angiography (CTA; endovascular and control arms) and digital subtraction angiography (DSA; endovascular arm only), blinded to all other data. CTA collaterals were graded with the Tan scale and DSA collaterals were scored by ASITN grade (American Society of Interventional and Therapeutic Neuroradiology collateral score). Descriptive statistics characterized CTA collateral grade in all DAWN subjects and DSA collaterals in the endovascular arm. The relationship between collateral grade and day 90 outcomes were separately analyzed for each treatment arm. Results: Collateral circulation to the ischemic territory was evaluated on CTA (n=144; median 2, 0-3) and DSA (n=57; median 2, 1-4) before thrombectomy in 161 DAWN subjects (mean age 69.8±13.6 years; 55.3% women; 91 endovascular therapy, 70 control). CTA revealed a broad range of collaterals (Tan grade 3, n=64 [44%]; 2, n=45 [31%]; 1, n=31 [22%]; 0, n=4 [3%]). DSA also showed a diverse range of collateral grades (ASITN grade 4, n=4; 3, n=22; 2, n=27; 1, n=4). Across treatment arms, baseline demographics, clinical variables except atrial fibrillation (41.6% endovascular versus 25.0% controls, P=0.04), and CTA collateral grades were balanced. Differences were seen across the 3 levels of collateral flow (good, fair, poor) for baseline National Institutes of Health Stroke Scale, blood glucose <150, diabetes, previous ischemic stroke, baseline and 24-hour core infarct volume, baseline and 24-hour Alberta Stroke Program Early CT Score, dramatic infarct progression, final Thrombolysis in Cerebral Infarction 2b+, and death. Collateral flow was a significant predictor of 90-day modified Rankin Scale score of 0 to 2 in the endovascular arm, with 43.7% (31/71) of subjects with good collaterals, 30.8% (16/52) of subjects with fair collaterals, and 17.7% (6/34) of subjects with poor collaterals reaching modified Rankin Scale score of 0 to 2 at 90 days (P=0.026). Conclusions: DAWN subjects enrolled at 6 to 24 hours after onset with limited infarct cores had a wide range of collateral grades on both CTA and DSA. Even in this late time window, better collaterals lead to slower stroke progression and better functional outcomes. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02142283.
AB - Background and Purpose: Collaterals govern the pace and severity of cerebral ischemia, distinguishing fast or slow progressors and corresponding therapeutic opportunities. The fate of sustained collateral perfusion or collateral failure is poorly characterized. We evaluated the nature and impact of collaterals on outcomes in the late time window DAWN trial (Diffusion-Weighted Imaging or Computed Tomography Perfusion Assessment With Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention With Trevo). Methods: The DAWN Imaging Core Lab prospectively scored collateral grade on baseline computed tomography angiography (CTA; endovascular and control arms) and digital subtraction angiography (DSA; endovascular arm only), blinded to all other data. CTA collaterals were graded with the Tan scale and DSA collaterals were scored by ASITN grade (American Society of Interventional and Therapeutic Neuroradiology collateral score). Descriptive statistics characterized CTA collateral grade in all DAWN subjects and DSA collaterals in the endovascular arm. The relationship between collateral grade and day 90 outcomes were separately analyzed for each treatment arm. Results: Collateral circulation to the ischemic territory was evaluated on CTA (n=144; median 2, 0-3) and DSA (n=57; median 2, 1-4) before thrombectomy in 161 DAWN subjects (mean age 69.8±13.6 years; 55.3% women; 91 endovascular therapy, 70 control). CTA revealed a broad range of collaterals (Tan grade 3, n=64 [44%]; 2, n=45 [31%]; 1, n=31 [22%]; 0, n=4 [3%]). DSA also showed a diverse range of collateral grades (ASITN grade 4, n=4; 3, n=22; 2, n=27; 1, n=4). Across treatment arms, baseline demographics, clinical variables except atrial fibrillation (41.6% endovascular versus 25.0% controls, P=0.04), and CTA collateral grades were balanced. Differences were seen across the 3 levels of collateral flow (good, fair, poor) for baseline National Institutes of Health Stroke Scale, blood glucose <150, diabetes, previous ischemic stroke, baseline and 24-hour core infarct volume, baseline and 24-hour Alberta Stroke Program Early CT Score, dramatic infarct progression, final Thrombolysis in Cerebral Infarction 2b+, and death. Collateral flow was a significant predictor of 90-day modified Rankin Scale score of 0 to 2 in the endovascular arm, with 43.7% (31/71) of subjects with good collaterals, 30.8% (16/52) of subjects with fair collaterals, and 17.7% (6/34) of subjects with poor collaterals reaching modified Rankin Scale score of 0 to 2 at 90 days (P=0.026). Conclusions: DAWN subjects enrolled at 6 to 24 hours after onset with limited infarct cores had a wide range of collateral grades on both CTA and DSA. Even in this late time window, better collaterals lead to slower stroke progression and better functional outcomes. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02142283.
KW - angiography
KW - collateral circulation
KW - perfusion
KW - thrombectomy
KW - tomography
UR - http://www.scopus.com/inward/record.url?scp=85125552888&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125552888&partnerID=8YFLogxK
U2 - 10.1161/STROKEAHA.121.034471
DO - 10.1161/STROKEAHA.121.034471
M3 - Article
C2 - 34727737
AN - SCOPUS:85125552888
VL - 29
SP - 742
EP - 748
JO - Stroke
JF - Stroke
SN - 0039-2499
IS - 2
ER -